collection
MENU ▼
Read by QxMD icon Read
search

Inflammatory Myopathies

shared collection
25 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28382787/2016-american-college-of-rheumatology-european-league-against-rheumatism-criteria-for-minimal-moderate-and-major-clinical-response-in-adult-dermatomyositis-and-polymyositis-an-international-myositis-assessment-and-clinical-studies-group-paediatric-rheumatology
#1
Rohit Aggarwal, Lisa G Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, Brian M Feldman, Chester V Oddis, Anthony A Amato, Hector Chinoy, Robert G Cooper, Maryam Dastmalchi, David Fiorentino, David Isenberg, James D Katz, Andrew Mammen, Marianne de Visser, Steven R Ytterberg, Ingrid E Lundberg, Lorinda Chung, Katalin Danko, Ignacio García-De la Torre, Yeong Wook Song, Luca Villa, Mariangela Rinaldi, Howard Rockette, Peter A Lachenbruch, Frederick W Miller, Jiri Vencovsky
OBJECTIVE: To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). METHODS: Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions...
May 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28129490/the-cutaneous-and-systemic-findings-associated-with-nuclear-matrix-protein-2-antibodies-in-adult-dermatomyositis-patients
#2
Anna Rogers, Lorinda Chung, Shufeng Li, Livia Casciola-Rosen, David F Fiorentino
OBJECTIVE: To characterize the cutaneous and systemic clinical phenotype of dermatomyositis patients with anti-NXP-2 antibodies. METHODS: We conducted a retrospective cohort analysis of 178 dermatomyositis patients seen at the Stanford University Clinic. Electronic chart review employing a keyword search strategy was performed to collect clinical and laboratory data. Anti-NXP-2 antibodies were assayed by immunoprecipitation using NXP-2 produced by in vitro transcription/translation...
January 27, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/27909085/a-negative-antinuclear-antibody-does-not-indicate-autoantibody-negativity-in-myositis-role-of-anticytoplasmic-antibody-as-a-screening-test-for-antisynthetase-syndrome
#3
Rohit Aggarwal, Namrata Dhillon, Noreen Fertig, Diane Koontz, Zengbiao Qi, Chester V Oddis
OBJECTIVE: To evaluate the utility of anticytoplasmic autoantibody (anti-CytAb) in antisynthetase antibody-positive (anti-SynAb+) patients. METHODS: Anti-SynAb+ patients were evaluated for antinuclear antibody (ANA) and anti-CytAb [cytoplasmic staining on indirect immunofluorescence (IIF)] positivity. Anti-SynAb+ patients included those possessing anti-Jo1 and other antisynthetase autoantibodies. Control groups included scleroderma, systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, and healthy subjects...
February 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28085235/dermatomyositis-patients-with-anti-nuclear-matrix-protein-2-autoantibodies-have-more-edema-more-severe-muscle-disease-and-increased-malignancy-risk
#4
Jemima Albayda, Iago Pinal-Fernandez, Wilson Huang, Cassie Parks, Julie Paik, Livia Casciola-Rosen, Sonye K Danoff, Cheilonda Johnson, Lisa Christopher-Stine, Andrew L Mammen
OBJECTIVES: Dermatomyositis (DM) patients typically present with proximal weakness and autoantibodies that are associated with distinct clinical phenotypes. We observed that DM patients with autoantibodies recognizing the nuclear matrix protein NXP-2 often presented with especially severe weakness. The aim of this study was to characterize clinical features associated with anti-NXP-2 autoantibodies. METHODS: 235 DM patients underwent testing for anti-NXP-2 autoantibodies...
January 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28082622/myositis-associated-usual-interstitial-pneumonia-has-a-better-survival-than-idiopathic-pulmonary-fibrosis
#5
Rohit Aggarwal, Christine McBurney, Frank Schneider, Samuel A Yousem, Kevin F Gibson, Kathleen Lindell, Carl R Fuhrman, Chester V Oddis
OBJECTIVE: To compare the survival outcomes between myositis-associated usual interstitial pneumonia (MA-UIP) and idiopathic pulmonary fibrosis (IPF-UIP). METHODS: Adult MA-UIP and IPF-UIP patients were identified using CTD and IPF registries. The MA-UIP cohort included myositis or anti-synthetase syndrome patients with interstitial lung disease while manifesting UIP on high-resolution CT chest and/or a lung biopsy revealing UIP histology. IPF subjects met American Thoracic Society criteria and similarly had UIP histopathology...
January 12, 2017: Rheumatology
https://www.readbyqxmd.com/read/27098592/update-on-the-pharmacological-treatment-of-adult-myositis
#6
C V Oddis
The management of patients with idiopathic inflammatory myopathy (IIM) remains a challenge given the systemic features beyond active myositis. That is, recognizing the inflammatory arthropathy, varying dermatomyositis rashes, and overt and occult features of interstitial lung disease in addition to myositis adds to the complexity of diagnosis and treatment of IIM. However, clinicians now have available many more immunosuppressive drugs as well as biologic agents for use in patients with myositis and other autoimmune diseases...
July 2016: Journal of Internal Medicine
https://www.readbyqxmd.com/read/27908312/calcinosis-in-poly-dermatomyositis-clinical-and-laboratory-predictors-and-treatment-options
#7
Micaela Fredi, Francesca Bartoli, Ilaria Cavazzana, Angela Ceribelli, Nice Carabellese, Angela Tincani, Minoru Satoh, Franco Franceschini
OBJECTIVES: We aimed to identify the possible clinical and laboratory predictors of calcinosis in a cohort of patients with a diagnosis of polymyositis (PM) and dermatomyositis (DM). METHODS: We carried out a retrospective analysis of a cohort of myositis patients attending our clinic between January 2013 and May 2014. RESULTS: 74 patients (58 females, 16 males) with PM (30 cases), DM (30 cases), overlap syndrome (13 cases) and inclusion body myositis (1 case) were enrolled...
November 14, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27452897/antimelanoma-differentiation-associated-protein-5-antibody-level-is-a-novel-tool-for-monitoring-disease-activity-in-rapidly-progressive-interstitial-lung-disease-with-dermatomyositis
#8
T Matsushita, K Mizumaki, M Kano, N Yagi, M Tennichi, A Takeuchi, Y Okamoto, Y Hamaguchi, A Murakami, M Hasegawa, M Kuwana, M Fujimoto, K Takehara
BACKGROUND: Antimelanoma differentiation-associated protein (anti-MDA)5 antibodies are associated with rapidly progressive interstitial lung disease (RP-ILD) in patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM). OBJECTIVES: We aimed to evaluate the relevance of monitoring anti-MDA5 antibody levels for the management of RP-ILD in patients with CADM or DM. METHODS: Twelve patients with CADM (n = 10) or DM (n = 2) accompanied by RP-ILD were included...
February 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/27684828/pulmonary-arterial-hypertension-in-idiopathic-inflammatory-myopathies-data-from-the-french-pulmonary-hypertension-registry-and-review-of-the-literature
#9
REVIEW
Sébastien Sanges, Cécile M Yelnik, Olivier Sitbon, Olivier Benveniste, Kuberaka Mariampillai, Mathilde Phillips-Houlbracq, Christophe Pison, Christophe Deligny, Jocelyn Inamo, Vincent Cottin, Luc Mouthon, David Launay, Marc Lambert, Pierre-Yves Hatron, Laurence Rottat, Marc Humbert, Eric Hachulla
Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies (IIMs) without extensive interstitial lung disease (ILD) has rarely been described in the medical literature. This study aimed to report all cases with association of PAH and IIM in the French Pulmonary Hypertension (PH) Registry, to identify IIM features associated with the presence of PAH, and to describe treatment modalities of these patients.All cases of IIM-PAH were retrieved from the French PH Registry, which gathers PH patients prospectively enrolled by 27 referral hospital centers across France...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27594777/the-diagnosis-and-treatment-of-antisynthetase-syndrome
#10
Leah J Witt, James J Curran, Mary E Strek
Anti-synthetase syndrome is an autoimmune condition, characterized by antibodies directed against an aminoacycl transfer RNA synthetase along with clinical features that can include interstitial lung disease, myositis, Raynaud's phenomenon, and arthritis. There is a higher prevalence and increased severity of interstitial lung disease in patients with anti-synthetase syndrome, as compared to dermatomyositis and polymyositis, inflammatory myopathies with which it may overlap phenotypically. Diagnosis is made by a multidisciplinary approach, synthesizing rheumatology and pulmonary evaluations, along with serologic, radiographic, and occasionally muscle and/or lung biopsy results...
September 2016: Clinical Pulmonary Medicine
https://www.readbyqxmd.com/read/26660480/predictive-factors-of-rapidly-progressive-interstitial-lung-disease-in-patients-with-clinically-amyopathic-dermatomyositis
#11
Y Xu, C S Yang, Y J Li, X D Liu, J N Wang, Q Zhao, W G Xiao, P T Yang
Clinically amyopathic dermatomyositis (CADM) is a unique subset of dermatomyositis, showing a high incidence of lung involvements. The aim of this study is to identify risk factors, other than melanoma differentiation-associated protein (MDA)-5, for developing rapidly progressive-interstitial lung disease (RP-ILD) in patients with CADM. Forty CADM patients, in whom 11 patients developed RP-ILD, were enrolled. Clinical features and laboratory findings were compared between the patients with and without RP-ILD...
January 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27578469/clinical-features-and-outcomes-of-interstitial-lung-disease-in-anti-jo-1-positive-antisynthetase-syndrome
#12
Ana C Zamora, Sumedh S Hoskote, Beatriz Abascal-Bolado, Darin White, Christian W Cox, Jay H Ryu, Teng Moua
BACKGROUND: Interstitial lung disease (ILD) is a common extra-muscular manifestation of antisynthetase (AS) syndrome. ILD prevalence is higher with anti-Jo-1 antibody positivity. Data on long-term outcomes in these patients are lacking. METHODS: Over 15 years, we identified subjects with anti-Jo-1 positive AS syndrome and ILD. Demographics, pulmonary function testing (PFT), high-resolution computed tomography (HRCT), histopathology, and long-term survival were analyzed...
September 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/26515574/immune-mediated-necrotizing-myopathy-update-on-diagnosis-and-management
#13
REVIEW
Pari Basharat, Lisa Christopher-Stine
The idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune disorders that target skeletal muscle. They are characterized by typical laboratory and clinical features including muscle weakness, elevated muscle enzymes, characteristic histopathology of muscle biopsies, as well as electromyography abnormalities. The IIMs are divided into polymyositis, dermatomyositis, inclusion body myositis, nonspecific myositis, and immune-mediated necrotizing myopathy (IMNM). IMNM is distinguished by the absence of primary inflammation on muscle biopsy...
December 2015: Current Rheumatology Reports
https://www.readbyqxmd.com/read/27651398/thigh-muscle-mri-in-immune-mediated-necrotising-myopathy-extensive-oedema-early-muscle-damage-and-role-of-anti-srp-autoantibodies-as-a-marker-of-severity
#14
Iago Pinal-Fernandez, Maria Casal-Dominguez, John A Carrino, Arash H Lahouti, Pari Basharat, Jemima Albayda, Julie J Paik, Shivani Ahlawat, Sonye K Danoff, Thomas E Lloyd, Andrew L Mammen, Lisa Christopher-Stine
OBJECTIVES: The aims of this study were to define the pattern of muscle involvement in patients with immune-mediated necrotising myopathy (IMNM) relative to those with other inflammatory myopathies and to compare patients with IMNM with different autoantibodies. METHODS: All Johns Hopkins Myositis Longitudinal Cohort subjects with a thigh MRI (tMRI) who fulfilled criteria for IMNM, dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) or clinically amyopathic DM (CADM) were included in the study...
September 20, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27421222/idiopathic-inflammatory-myositis
#15
REVIEW
Joanna Tieu, Ingrid E Lundberg, Vidya Limaye
Knowledge on idiopathic inflammatory myopathy (IIM) has evolved with the identification of myositis-associated and myositis-specific antibodies, development of histopathological classification and the recognition of how these correlate with clinical phenotype and response to therapy. In this paper, we outline key advances in diagnosis and histopathology, including the more recent identification of antibodies associated with immune-mediated necrotising myopathy (IMNM) and inclusion body myositis (IBM). Ongoing longitudinal observational cohorts allow further classification of these patients with IIM, their predicted clinical course and response to specific therapies...
February 2016: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27247435/temporal-relationship-between-cancer-and-myositis-identifies-two-distinctive-subgroups-of-cancers-impact-on-cancer-risk-and-survival-in-patients-with-myositis
#16
Eun Ha Kang, Sang Jin Lee, Dana P Ascherman, Yun Jong Lee, Eun Young Lee, Eun Bong Lee, Yeong Wook Song
OBJECTIVES: The aim was to compare standardized incidence ratios (SIRs) of cancers temporally related and unrelated to active myositis in patients with myositis. METHODS: Fifty-two cancer cases were identified in 281 myositis patients. SIRs of cancers having temporal overlap with the active phase of myositis [cancers concurrent with active myositis (CAM), n = 30] and cancers not having such temporal overlap [cancers non-concurrent with active myositis (CNM), n = 22] were compared in 281 patients...
September 2016: Rheumatology
https://www.readbyqxmd.com/read/27121778/rituximab-in-the-treatment-of-inflammatory-myopathies-a-review
#17
REVIEW
Serena Fasano, Patrick Gordon, Raouf Hajji, Esthela Loyo, David A Isenberg
Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015...
January 2017: Rheumatology
https://www.readbyqxmd.com/read/27102182/management-of-myositis-related-interstitial-lung-disease
#18
REVIEW
Julie Morisset, Cheilonda Johnson, Eric Rich, Harold R Collard, Joyce S Lee
Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature...
November 2016: Chest
https://www.readbyqxmd.com/read/26826433/cardiac-involvement-in-polymyositis-and-dermatomyositis
#19
REVIEW
Maria Giovanna Danieli, Chiara Gelardi, Federico Guerra, Paolo Cardinaletti, Veronica Pedini, Armando Gabrielli
No abstract text is available yet for this article.
May 2016: Autoimmunity Reviews
https://www.readbyqxmd.com/read/26034044/a-review-of-salivary-gland-histopathology-in-primary-sj%C3%A3-gren-s-syndrome-with-a-focus-on-its-potential-as-a-clinical-trials-biomarker
#20
REVIEW
Benjamin A Fisher, Rachel M Brown, Simon J Bowman, Francesca Barone
Salivary gland changes, characterised by a focal lymphocytic sialadenitits, play an important role in the diagnosis of primary Sjögren's syndrome (PSS) and were first described over 40 years ago. Recent evidence suggests that minor salivary gland biopsy may also provide information useful for prognostication and stratification, yet difficulties may arise in the histopathological interpretation and scoring, and evidence exists that reporting is variable. With the increasing number of actual and proposed clinical trials in PSS, we review the evidence that might support the role of histopathology as a biomarker for stratification and response to therapy and highlight areas where further validation work is required...
September 2015: Annals of the Rheumatic Diseases
label_collection
label_collection
7937
1
2
2016-09-24 15:49:39
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"